11/28 Business Wire Health: Oncology News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Oncology News - Health: Oncology News Distributed by Business Wire ChemGenex's Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency November 27, 2009 at 8:00 am MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid. Validation of the MAA indicates that ChemGenex’s application, submitted Research and Markets: Prostate Cancer Therapeutics - a Global Market Perspective November 27, 2009 at 7:00 am DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/50344c/prostate_cancer_th) has announced the addition of the "Prostate Cancer Therapeutics - A Global Market Perspective" report to their offering. Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.